^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SAL008

i
Other names: SAL008, JK08
Associations
Company:
Shenzhen Salubris
Drug class:
CTLA4 inhibitor, IL-15 stimulant
Associations
1m
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
P1/2, N=263, Active, not recruiting, Salubris Biotherapeutics Inc | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • SAL008
7ms
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
P1/2, N=263, Recruiting, Salubris Biotherapeutics Inc | N=149 --> 263
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Keytruda (pembrolizumab) • SAL008
1year
Clinical • P1/2 data • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
|
CTLA4 expression
|
SAL008
over1year
Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer (ESMO 2023)
Conclusions At the dose levels evaluated to date, JK08 has been well tolerated, demonstrating preliminary disease stability & anticipated modulation of target immune cell populations in aggressive heavily pre-treated solid tumors. These results provide an initial characterization of JK08 biology & activity.
P1/2 data • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
|
CD8 expression
|
SAL008
over1year
A phase 1 / 2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors (AACR 2023)
Four tumor specific expansion cohorts will be initiated once dose and schedule are established from dose escalation and include melanoma, breast cancer, colorectal cancer, and a basket of advanced solid tumors. Response will be assessed every 9 weeks per RECIST v1.1.
Clinical • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
|
CTLA4 expression
|
SAL008
2years
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
SAL008